文献速递儿科与产科急症

阴道分娩产程椎管内镇痛与严重孕产妇并发症的关系

Use of Labor Neuraxial Analgesia for Vaginal Delivery and Severe Maternal Morbidity.
PubMed 文献 · JAMA Netw Open · 2022-02-01
一句话结论基于纽约2010–2017年575 524例首次阴道分娩的横断面研究显示,产程椎管内镇痛与严重孕产妇并发症风险降低14%相关(aOR 0.86)。

该研究基于纽约2010年1月至2017年12月出院记录,纳入575 524例15–49岁首次阴道分娩产妇,比较椎管内镇痛(硬膜外或腰硬联合)与无椎管内镇痛的严重孕产妇并发症(SMM)。加权后椎管内镇痛与SMM风险降低相关(aOR 0.86,95%CI 0.82–0.90),该关联在非西班牙裔白人女性和少数族裔女性间、低危和高危女性间相似;21%(95%CI 14–28)的关联通过降低产后出血风险介导。作者认为增加产程椎管内镇痛的可及性和使用可能有助于改善孕产妇健康结局。

要点

  • 575 524例首次阴道分娩产妇中,椎管内镇痛与SMM风险降低相关(aOR 0.86,95%CI 0.82–0.90)。
  • 加权前SMM发生率:椎管内镇痛组1.3%(3486/272 291)vs 无椎管内镇痛组1.4%(4226/302 603),风险差-0.12/100(95%CI -0.17至-0.07)。
  • 椎管内镇痛与SMM降低的关联在非西班牙裔白人女性和少数族裔女性间、低危和高危女性间相似。
  • 21%(95%CI 14–28)的SMM关联通过降低产后出血风险介导,产后出血是SMM的次要结局。
  • 作者认为增加产程椎管内镇痛的可及性和使用可能有助于改善孕产妇健康结局。

适用人群与场景

  • 15–49岁、于2010年1月至2017年12月在纽约州医院进行首次阴道分娩的产妇,数据来自医院出院记录。

诊断标准与关键阈值

  • SMM采用美国疾病控制与预防中心(CDC)定义。
  • 次要结局为产后出血(PPH)。
  • 按种族和族裔分层:非西班牙裔白人 vs 少数族裔(包括非西班牙裔亚裔或太平洋岛民、非西班牙裔黑人、西班牙裔及其他种族和族裔)。
  • 按产科患者共病指数分层:低危 vs 高危。

研究设计与关键结果

  • 研究类型:基于人群的横断面研究;样本量575 524例;地点纽约;时间2010年1月至2017年12月;数据分析时间2020年11月至2021年11月。
  • 人群平均(SD)年龄28(6)岁;非西班牙裔亚裔或太平洋岛民46 065例(8.0%),非西班牙裔黑人88 577例(15.4%),西班牙裔104 866例(18.2%),非西班牙裔白人258 276例(44.9%),其他种族和族裔74 534例(13.0%)。
  • 低危组400 346例(69.6%),高危组175 178例(30.4%);272 921例(47.4%)接受椎管内镇痛。
  • SMM发生于7712例(1.3%),其中2748例(35.6%)发生产后出血。
  • 加权前SMM发生率:椎管内镇痛组1.3%(3486/272 291)vs 无椎管内镇痛组1.4%(4226/302 603),风险差-0.12/100(95%CI -0.17至-0.07)。
  • 加权后椎管内镇痛与SMM的aOR为0.86(95%CI 0.82–0.90)。
  • 椎管内镇痛与SMM风险降低的关联在非西班牙裔白人女性和少数族裔女性间相似,在低危和高危女性间也相似。
  • 椎管内镇痛与SMM风险关联中,21%(95%CI 14–28)通过降低产后出血风险介导。

证据类型、等级与局限

  • 证据类型:基于人群的横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,产程椎管内镇痛与阴道分娩严重孕产妇并发症风险降低14%相关(aOR 0.86,95%CI 0.82–0.90)。
  • 作者认为,增加产程椎管内镇痛的可及性和使用可能有助于改善孕产妇健康结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Addressing severe maternal morbidity (SMM) is a public health priority in the US. Use of labor neuraxial analgesia for vaginal delivery is suggested to reduce the risk of postpartum hemorrhage (PPH), the leading cause of preventable severe maternal morbidity.

OBJECTIVE: To assess the association between the use of labor neuraxial analgesia for vaginal delivery and SMM.

DESIGN, SETTING, AND PARTICIPANTS: In this population-based cross-sectional study, women aged 15 to 49 years undergoing their first vaginal delivery were included. Data were taken from hospital discharge records from New York between January 2010 and December 2017. Data were analyzed from November 2020 to November 2021.

EXPOSURES: Neuraxial analgesia (ie, epidural or combined spinal-epidural) vs no neuraxial analgesia.

MAIN OUTCOMES AND MEASURES: The primary outcome was SMM, as defined by the US Centers for Disease Control and Prevention, and the secondary outcome was PPH. Adjusted odds ratios (aORs) and 95% CIs of SMM associated with neuraxial analgesia were estimated using the inverse propensity score-weighting method and stratified according to race and ethnicity (non-Hispanic White vs racial and ethnic minority women, including non-Hispanic Asian or Pacific Islander, non-Hispanic Black, Hispanic, and other race and ethnicity) and to the comorbidity index for obstetric patients (low-risk vs high-risk women). The proportion of the association of neuraxial analgesia with the risk of SMM mediated through PPH was estimated using mediation analysis.

RESULTS: Of 575 524 included women, the mean (SD) age was 28 (6) years, and 46 065 (8.0%) were non-Hispanic Asian or Pacific Islander, 88 577 (15.4%) were non-Hispanic Black, 104 866 (18.2%) were Hispanic, 258 276 (44.9%) were non-Hispanic White, and 74 534 (13.0%) were other race and ethnicity. A total of 400 346 women (69.6%) were in the low-risk group and 175 178 (30.4%) in the high-risk group, and 272 921 women (47.4%) received neuraxial analgesia. SMM occurred in 7712 women (1.3%), of which 2748 (35.6%) had PPH. Before weighting, the incidence of SMM was 1.3% (3486 of 272 291) with neuraxial analgesia compared with 1.4% (4226 of 302 603) without neuraxial analgesia (risk difference, -0.12 per 100; 95% CI, -0.17 to -0.07). After weighting, the aOR of SMM associated with neuraxial analgesia was 0.86 (95% CI, 0.82-0.90). Decreased risk of SMM associated with neuraxial analgesia was similar between non-Hispanic White women and racial and ethnic minority women and between low-risk and high-risk women. More than one-fifth (21%; 95% CI, 14-28) of the observed association of neuraxial analgesia with the risk of SMM was mediated through the decreased risk of PPH.

CONCLUSIONS AND RELEVANCE: Findings from this study suggest that use of neuraxial analgesia for vaginal delivery is associated with a 14% decrease in the risk of SMM. Increasing access to and utilization of labor neuraxial analgesia may contribute to improving maternal health outcomes.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Guglielminotti J, Landau R, Daw J, et al. Use of Labor Neuraxial Analgesia for Vaginal Delivery and Severe Maternal Morbidity. JAMA Netw Open. 2022. PMID: 35191971. doi:10.1001/jamanetworkopen.2022.0137

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。